Does Rallies show 13F holders for TRAW?

Yes. Rallies tracks hedge fund and 13F ownership data for TRAW, including fund names, share counts, latest tracked quarter, and position changes when available.

Is TRAW research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TRAW. It does not provide personalized investment advice.

TRAW (Traws Pharma, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Traws Pharma, Inc. Common Stock (TRAW) is a publicly traded Healthcare sector company. As of May 21, 2026, TRAW trades at $1.70 with a market cap of $26.67M and a P/E ratio of -0.94. TRAW moved +3.14% today. Year to date, TRAW is +25.58%; over the trailing twelve months it is +29.60%. Its 52-week range spans $0.97 to $19.44. Rallies surfaces TRAW's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns TRAW stock?

Hedge funds tracked by Rallies that own TRAW include Orbimed Advisors. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Traws Pharma, Inc. Common Stock.

TRAW Key Metrics

Key financial metrics for TRAW
Metric	Value
Price	$1.70
Market Cap	$26.67M
P/E Ratio	-0.94
EPS	$-1.71
Dividend Yield	0.00%
52-Week High	$19.44
52-Week Low	$0.97
Volume	3.27K
Avg Volume	0
Revenue (TTM)	$2.73M
Net Income	$-19.43M
Gross Margin	0.00%

Top Hedge Funds Holding TRAW

Orbimed Advisors holds 605.53K shares of TRAW, changed +0.00% as of Mar 31, 2026.

Latest TRAW News

Traws Pharma Raises $60M PIPE, Eyes Q2 Human Flu Trial — May 15, 2026
Traws Pharma Targets Hantavirus With New Antiviral Program for 30–50% Fatality Disease — May 8, 2026
Traws Pharma Secures $60M PIPE ($10M Upfront), Plans Q2 Influenza Challenge Trial — Apr 15, 2026
Traws Pharma Raises $10M Upfront, Up to $60M for UK Flu Challenge — Apr 15, 2026
Traws Pharma’s Ratutrelvir Cuts Adverse Events to 10% Versus 23.3% in 90-Patient Trial — Feb 19, 2026

Recent TRAW Insider Trades

ORBIMED ADVISORS LLC bought 597.73K (~$998.21K) on Apr 16, 2026.

TRAW Analyst Consensus

TRAW analyst coverage data. Average price target: $0.00.

Common questions about TRAW

Who owns TRAW stock?: Hedge funds tracked by Rallies that own TRAW include Orbimed Advisors. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Traws Pharma, Inc. Common Stock.
Does Rallies show 13F holders for TRAW?: Yes. Rallies tracks hedge fund and 13F ownership data for TRAW, including fund names, share counts, latest tracked quarter, and position changes when available.
Is TRAW research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TRAW. It does not provide personalized investment advice.